Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 7—July 2021
Research Letter

Postoperative Paenibacillus thiaminolyticus Wound Infection, Switzerland

Riccardo Di Micco, Matthias Schneider, and Reto NüeschComments to Author 
Author affiliations: Spital Schwyz, Schwyz, Switzerland (R. Di Micco, M. Schneider, R. Nüesch); University of Basel, Basel, Switzerland (R. Nüesch)

Main Article


Comparison of MIC and SS of antimicrobial drugs in blood 4 hours after intravenous administration to treat Paenibacillus thiaminolyticus in a patient, Switzerland*

Antimicrobial drug† MIC SSC
Amoxicillin/clavulanate 0.064 mg/L 1.2 mg/L
Tetracycline 12 mg/L 2.8 mg/L
Trimethoprim/sulfamethoxazole‡ <0.094 mg/L 1.5–3 mg/L
Clindamycin 0.38 mg/L 23 mg/L
Ciprofloxacin 0.19 mg/L 4.56 mg/L
*No specific clinical breakpoints have been established for Paenibacillus spp. We used European Committee on Antimicrobial Susceptibility Testing pharmacokinetics and pharmacodynamics to determine antimicrobial susceptibility. SSC, steady state concentration.

†Antimicrobial drugs were administered at the recommended doses reported in the manufacturer the data sheets (, ‡Trimethoprim/sulfamethoxazole is dose dependent.

Main Article

Page created: May 12, 2021
Page updated: June 17, 2021
Page reviewed: June 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.